Leveraging Illuccix’s® Established Imaging Performance: An Intraindividual Comparison with Gozellix® PET

Learn more 🔗 bit.ly/40wNM6T

#PSMAPET #Radiology #CaseSeries #MolecularImaging #PETCT #RadEd #MedEd

🔷 Findings highlight how advanced imaging may refine prognosis and guide more personalized treatment strategies in prostate cancer.

🔗 Read more: bit.ly/ONCOnews-11M...

#ONCOnews #OncoAlert #OncEd #ProstateCancer #PSMAPET #Oncology #CancerResearch #CancerImaging #PrecisionMedicine #Urology #Cancer

How has PSMA PET changed prostate cancer management?

🎓 Watch the full PSMA PET video case series presented by Louis Mazzarelli, MD here: bit.ly/4u1Ht8y

#PSMAPET #Radiology #CaseSeries #ProstateCancer #MolecularImaging #PETCT #RadEd #MedEd

Sabine D. Brookman-May: Excellent Review on PSMA PET for Prostate Cancer Diagnosis - OncoDaily Sabine D. Brookman-May: Excellent Review on PSMA PET for Prostate Cancer Diagnosis / cancer, european urology, OncoDaily, Oncology, prostate cancer, PSMA,

Excellent Review on PSMA PET for Prostate Cancer Diagnosis - Sabine D. Brookman-May
@brookmans76.bsky.social

oncodaily.com/science/psma...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #PSMAPET #ProstateCancer

🎥 New on #OncologyBytes from IUCS2024
Dr. James Artingstall: PSMA PET detects prostate cancer relapse even at very low PSA levels.
📊 Early imaging = better treatment decisions.
📺 Watch: youtu.be/28JEZpt7jSM
🌐 Learn more at: oncoassist.com

#ProstateCancer #PSMAPET #BiochemicalRelapse #Radiotherapy

Amazing discussion this morning on imaging in the BCR setting of #prostatecancer
#APCCCDiagnostics25
#PSMAPET by Irene Burger

SMA-PET in Biochemically Recurrent Prostate Cancer: A Paradigm Shift - OncoDaily SMA-PET in Biochemically Recurrent Prostate Cancer: A Paradigm Shift / Adrien Holzgreve, cancer, Clayton P. Smith, CT, disease, Gustavo Viani, Kevyn J. Clark,

SMA-PET in Biochemically Recurrent Prostate Cancer: A Paradigm Shift

oncodaily.com/science/217834

#Cancer #CTdisease #OncoDaily #Oncology #Health #ProstateCancer #PSMAPET #Medicine

Conventional imaging understages high-risk nonmetastatic prostate cancer.
☢️PSMA-PET was positive in 84% of cases, detecting M1 disease in 46%, polymetastatic in 24%.
#ProstateCancer #PSMAPET #Oncology @oncoalert.bsky.social @mjmorrismd.bsky.social
doi:10.1001/jamanetworkopen.2024.52971

#PROSCA24 on #BlueSky @oncoalert.bsky.social
Great talk on #PSMAPET - although it is superior for LN+ it is not infallible & isn't indicated in all patients @pgrivasmdphd.bsky.social welcome to #BlueSky

How do we think about staging lymph nodes in #prostatecancer now that we have #PSMAPET?

And more importantly, what do we do when we find them?

Join us at #EAU21 at 3pm CET today July 11 as we discuss this new dilemma.

@USANZUrology @urologytraining @Uroweb @eau_yuo